Immunome Inc [IMNM] stock is trading at $11.15, up 13.54%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMNM shares have gain 18.18% over the last week, with a monthly amount drifted -7.93%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on November 08, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $30. Previously, Piper Sandler started tracking the stock with Overweight rating on May 31, 2024, and set its price target to $27. On April 30, 2024, JP Morgan initiated with a Overweight rating and assigned a price target of $24 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $35 on April 15, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $30 as its price target on January 29, 2024. Wedbush started tracking with a Outperform rating for this stock on December 19, 2023, and assigned it a price target of $12. In a note dated October 29, 2021, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $35 on this stock.
Immunome Inc [IMNM] stock has fluctuated between $6.93 and $30.96 over the past year. Currently, Wall Street analysts expect the stock to reach $30.33 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $11.15 at the most recent close of the market. An investor can expect a potential return of 172.02% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Immunome Inc [NASDAQ:IMNM] reported sales of 10.13M for the trailing twelve months, which represents a drop of -18.37%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -31.34%, Pretax Profit Margin comes in at -30.15%, and Net Profit Margin reading is -30.15%. To continue investigating profitability, this company’s Return on Assets is posted at -1.19, Equity is -1.4 and Total Capital is -1.46. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.78 points at the first support level, and at 10.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.42, and for the 2nd resistance point, it is at 11.68.
Ratios To Look Out For
For context, Immunome Inc’s Current Ratio is 6.17. Also, the Quick Ratio is 6.17, while the Cash Ratio stands at 3.94. Considering the valuation of this stock, the price to sales ratio is 71.62, the price to book ratio is 3.13.
Transactions by insiders
Recent insider trading involved SIEGALL CLAY B, President and CEO, that happened on Nov 21 ’24 when 66057.0 shares were purchased. President and CEO, SIEGALL CLAY B completed a deal on Nov 22 ’24 to buy 33943.0 shares. Meanwhile, Chief Medical Officer Lechleider Robert bought 15805.0 shares on Nov 21 ’24.
